Menu
GeneBe

CTNS

cystinosin, lysosomal cystine transporter, the group of Solute carrier family 66

Basic information

Region (hg38): 17:3636458-3663103

Links

ENSG00000040531NCBI:1497OMIM:606272HGNC:2518Uniprot:O60931AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • cystinosis (Definitive), mode of inheritance: AR
  • nephropathic cystinosis (Definitive), mode of inheritance: AR
  • nephropathic cystinosis (Strong), mode of inheritance: AR
  • juvenile nephropathic cystinosis (Strong), mode of inheritance: AR
  • ocular cystinosis (Strong), mode of inheritance: AR
  • nephropathic cystinosis (Definitive), mode of inheritance: AR
  • nephropathic infantile cystinosis (Supportive), mode of inheritance: AR
  • juvenile nephropathic cystinosis (Supportive), mode of inheritance: AR
  • ocular cystinosis (Supportive), mode of inheritance: AR
  • juvenile nephropathic cystinosis (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
CystinosisARBiochemical; Endocrine; Ophthalmologic; RenalCystine-depleting agents (cysteamine) instituted at an early age can be beneficial related to manifestations affecting multiple organ systems, perhaps including cognitive development, as well as renal manifestations (renal tubular Fanconi syndrome and glomerular damage), though renal transplantation may be necessary; Surveillance for renal manifestations and related sequelae can allow early detection and management of disease with (in addition to cystine-depleting agents), replacement of renal losses; Dietary management (eg, ensuring sufficient caloric intake, and with vitamin D and phosphate supplementation) can be beneficial related to potential failure to thrive and hypophosphatemic rickets; Cysteamine eyedrops can be beneficial related to ophthalmologic sequelae; Surveillance for endocrine manifestations (eg, hypothyroidism, or hypogonadism in males) can allow early detection and medical management, including potential use of growth hormone in order to optimize height in some individualsBiochemical; Endocrine; Musculoskeletal; Ophthalmologic; Renal6038997; 4914142; 5443335; 406375; 333912; 7112129; 3307383; 3335962; 3550461; 3674101; 3821824; 3335962; 3185663; 3292915; 381441; 2230837; 552398; 8455682; 8172256; 7593434; 9537412; 10556299; 10417278; 10444339; 10625078; 11001803; 10673275; 12110740; 12442267; 16603246; 17643777; 19863563; 20301574; 20803298; 20814825; 21305353; 21784456; 21868618; 21371554; 21900880; 22903658; 23001048; 23462307; 23538568; 25165189

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CTNS gene.

  • Nephropathic cystinosis (280 variants)
  • Ocular cystinosis;Juvenile nephropathic cystinosis;Inborn genetic diseases (195 variants)
  • Inborn genetic diseases;Ocular cystinosis;Juvenile nephropathic cystinosis (179 variants)
  • Ocular cystinosis (157 variants)
  • Cystinosis (91 variants)
  • not provided (75 variants)
  • Ocular cystinosis;Juvenile nephropathic cystinosis;Nephropathic cystinosis (32 variants)
  • Nephropathic cystinosis;Ocular cystinosis;Juvenile nephropathic cystinosis (30 variants)
  • not specified (22 variants)
  • Inborn genetic diseases (19 variants)
  • Ocular cystinosis;Inborn genetic diseases;Juvenile nephropathic cystinosis (12 variants)
  • Inborn genetic diseases;Juvenile nephropathic cystinosis;Ocular cystinosis (5 variants)
  • Juvenile nephropathic cystinosis (5 variants)
  • Juvenile nephropathic cystinosis;Ocular cystinosis;Inborn genetic diseases (4 variants)
  • Ocular cystinosis;Nephropathic cystinosis;Juvenile nephropathic cystinosis (4 variants)
  • Juvenile nephropathic cystinosis;Inborn genetic diseases;Ocular cystinosis (3 variants)
  • Infantile nephropathic cystinosis (3 variants)
  • Cystinosis, atypical nephropathic (2 variants)
  • Nephropathic cystinosis;Juvenile nephropathic cystinosis;Ocular cystinosis (2 variants)
  • Nephrotic syndrome (1 variants)
  • See cases (1 variants)
  • CTNS-related condition (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CTNS gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
133
clinvar
3
clinvar
139
missense
8
clinvar
15
clinvar
96
clinvar
11
clinvar
3
clinvar
133
nonsense
8
clinvar
18
clinvar
26
start loss
1
clinvar
1
frameshift
25
clinvar
20
clinvar
1
clinvar
46
inframe indel
1
clinvar
4
clinvar
8
clinvar
13
splice donor/acceptor (+/-2bp)
5
clinvar
25
clinvar
1
clinvar
31
splice region
3
1
10
32
1
47
non coding
2
clinvar
77
clinvar
52
clinvar
58
clinvar
189
Total 50 82 185 196 65

Highest pathogenic variant AF is 0.0000920

Variants in CTNS

This is a list of pathogenic ClinVar variants found in the CTNS region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
17-3636480-A-T Ocular cystinosis • Nephropathic cystinosis Uncertain significance (Jan 12, 2018)889009
17-3636541-T-C Ocular cystinosis • Nephropathic cystinosis Benign (Oct 05, 2018)322815
17-3636552-C-G Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 12, 2018)889705
17-3636564-C-T Ocular cystinosis • Nephropathic cystinosis Uncertain significance (Jan 13, 2018)322816
17-3636585-G-A Nephropathic cystinosis • Ocular cystinosis Likely benign (Jan 12, 2018)322817
17-3636603-C-T Ocular cystinosis • Nephropathic cystinosis Benign (Oct 05, 2018)322818
17-3636610-A-G Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Apr 27, 2017)891259
17-3636632-T-C Ocular cystinosis • Nephropathic cystinosis Uncertain significance (Jan 12, 2018)322819
17-3636697-G-T Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 12, 2018)322820
17-3636699-C-T Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 12, 2018)322821
17-3636748-G-A Nephropathic cystinosis • Ocular cystinosis Benign (Jun 19, 2018)322822
17-3636789-A-C Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 13, 2018)322823
17-3636803-G-A Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 12, 2018)322824
17-3636842-A-G Nephropathic cystinosis • Ocular cystinosis Benign (Jan 13, 2018)322825
17-3637123-T-C Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 13, 2018)322826
17-3637200-C-A Ocular cystinosis • Nephropathic cystinosis Uncertain significance (Jan 13, 2018)322827
17-3637262-A-T Ocular cystinosis • Nephropathic cystinosis Uncertain significance (Jan 12, 2018)322828
17-3637289-A-C Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 13, 2018)322829
17-3637312-C-T Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 12, 2018)322830
17-3637312-CAG-C Cystinosis • Nephropathic cystinosis Uncertain significance (Jun 14, 2016)322831
17-3637329-T-C Nephropathic cystinosis • Ocular cystinosis Uncertain significance (Jan 13, 2018)322832
17-3639977-A-G Benign (Jul 15, 2018)1277327
17-3640187-G-A Nephropathic cystinosis Likely pathogenic (Jun 05, 2023)552524
17-3640199-C-T Nephropathic cystinosis Uncertain significance (Jul 31, 2017)553156
17-3640207-A-T Ocular cystinosis;Juvenile nephropathic cystinosis;Inborn genetic diseases Pathogenic (Mar 18, 2023)1391189

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CTNSprotein_codingprotein_codingENST00000381870 1125075
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0003090.9881256890591257480.000235
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.9182712321.170.00001622632
Missense in Polyphen8871.6371.2284895
Synonymous-1.7711895.91.230.00000786794
Loss of Function2.23919.70.4588.78e-7225

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003040.000304
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.000.00
European (Non-Finnish)0.0003880.000387
Middle Eastern0.00005440.0000544
South Asian0.0001960.000196
Other0.0003260.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Cystine/H(+) symporter thought to transport cystine out of lysosomes. Plays an important role in melanin synthesis, possibly by preventing melanosome acidification and subsequent degradation of tyrosinase TYR. {ECO:0000269|PubMed:22649030}.;
Disease
DISEASE: Cystinosis, adult, non-nephropathic type (CTNSANN) [MIM:219750]: A form of cystinosis, a lysosomal storage disease due to defective transport of cystine across the lysosomal membrane. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. Cystinosis adult non-nephropathic type is characterized by ocular features and a benign course. Patients manifest mild photophobia due to conjunctival and corneal cystine crystals. {ECO:0000269|PubMed:10625078}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cystinosis, late-onset juvenile or adolescent nephropathic type (CTNSJAN) [MIM:219900]: A form of cystinosis, a lysosomal storage disease due to defective transport of cystine across the lysosomal membrane. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. Late-onset juvenile or adolescent nephropathic cystinosis is an intermediated form, manifesting first at age 10 to 12 years with proteinuria due to glomerular damage rather than with the manifestations of tubular damage that occur first in infantile cystinosis. There is no excess amino aciduria and stature is normal. Photophobia, late development of pigmentary retinopathy, and chronic headaches are features. {ECO:0000269|PubMed:10444339, ECO:0000269|PubMed:12442267, ECO:0000269|PubMed:9792862}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Lysosome - Homo sapiens (human);Beta-mercaptolactate-cysteine disulfiduria;Cysteine Metabolism;Cystinosis, ocular nonnephropathic;Transport of inorganic cations/anions and amino acids/oligopeptides;SLC-mediated transmembrane transport;Transport of small molecules;Miscellaneous transport and binding events (Consensus)

Recessive Scores

pRec
0.363

Intolerance Scores

loftool
0.0634
rvis_EVS
-0.18
rvis_percentile_EVS
40.56

Haploinsufficiency Scores

pHI
0.0798
hipred
N
hipred_score
0.414
ghis
0.468

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.561

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Ctns
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; pigmentation phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; vision/eye phenotype;

Zebrafish Information Network

Gene name
ctns
Affected structure
trunk
Phenotype tag
abnormal
Phenotype quality
curved

Gene ontology

Biological process
lens development in camera-type eye;cellular amino acid metabolic process;glutathione metabolic process;ion transport;brain development;long-term memory;grooming behavior;adult walking behavior;visual learning;negative regulation of hydrogen peroxide biosynthetic process;positive regulation of mitochondrial membrane potential;L-cystine transport;melanin biosynthetic process;ATP metabolic process;cognition;transmembrane transport
Cellular component
lysosome;lysosomal membrane;early endosome;late endosome;vacuolar membrane;plasma membrane;integral component of membrane;melanosome;intracellular membrane-bounded organelle;intermediate filament cytoskeleton;extracellular exosome
Molecular function
L-cystine transmembrane transporter activity